Delayed
OTC Markets
|
5-day change
|
1st Jan Change
|
- USD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,154
|
193.1
|
65.46
|
145.1
|
335.8
|
-
|
-
|
Enterprise Value (EV)
1 |
838.6
|
-16.69
|
-57.35
|
145.1
|
335.8
|
335.8
|
335.8
|
P/E ratio
|
-15.6
x
|
-1.54
x
|
-0.71
x
|
-1.49
x
|
-4.07
x
|
-3.57
x
|
-3.37
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
86.3
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
86.3
x
|
EV / EBITDA
|
-16,595,135
x
|
-1,524,466
x
|
-709,045
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-22.1
x
|
-1.88
x
|
-0.77
x
|
-
|
-4.6
x
|
-3.55
x
|
-2.68
x
|
FCF Yield
|
-4.53%
|
-53.3%
|
-130%
|
-
|
-21.7%
|
-28.1%
|
-37.4%
|
Price to Book
|
3.76
x
|
0.98
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
35,996
|
36,229
|
36,366
|
51,635
|
56,253
|
-
|
-
|
Reference price
2 |
32.05
|
5.330
|
1.800
|
2.810
|
5.970
|
5.970
|
5.970
|
Announcement Date
|
3/25/21
|
3/17/22
|
3/9/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
3.893
|
EBITDA
|
-29.28
|
-69.52
|
-126.7
|
-92.32
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.33
|
-69.57
|
-126.9
|
-92.83
|
-86.46
|
-85.73
|
-112.4
|
-138.2
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,548.81%
|
Earnings before Tax (EBT)
1 |
-35.26
|
-67.25
|
-125.6
|
-91.17
|
-82.44
|
-80.88
|
-104.1
|
-123.3
|
Net income
1 |
-35.26
|
-67.25
|
-125.6
|
-91.17
|
-82.44
|
-81.62
|
-109.9
|
-135.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,479.09%
|
EPS
2 |
-16.99
|
-2.050
|
-3.470
|
-2.520
|
-1.880
|
-1.468
|
-1.670
|
-1.772
|
Free Cash Flow
1 |
-24.7
|
-52.29
|
-102.9
|
-85.27
|
-
|
-73
|
-94.5
|
-125.5
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-3,223.73%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/24/20
|
3/25/21
|
3/17/22
|
3/9/23
|
3/12/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-25.96
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-26.08
|
-25.68
|
-23.17
|
-22.12
|
-21.85
|
-21.56
|
-20.03
|
-24.01
|
-20.86
|
-20.25
|
-21.4
|
-21.79
|
-22.25
|
-27.49
|
-29.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-25.87
|
-25.51
|
-22.93
|
-21.65
|
-21.08
|
-20.88
|
-19.15
|
-23.01
|
-19.41
|
-18.22
|
-20.38
|
-20.88
|
-21.4
|
-25.06
|
-27.05
|
Net income
1 |
-25.87
|
-25.51
|
-22.93
|
-21.65
|
-21.08
|
-20.88
|
-19.15
|
-23.01
|
-19.41
|
-18.22
|
-20.65
|
-21.06
|
-21.5
|
-28.37
|
-30.36
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7100
|
-0.7000
|
-0.6300
|
-0.6000
|
-0.5900
|
-0.5700
|
-0.5200
|
-0.4500
|
-0.3400
|
-0.3500
|
-0.3867
|
-0.3683
|
-0.3667
|
-0.4450
|
-0.4675
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/11/22
|
8/9/22
|
11/8/22
|
3/9/23
|
5/9/23
|
8/11/23
|
11/6/23
|
3/12/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
315
|
210
|
123
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-24.7
|
-52.3
|
-103
|
-85.3
|
-
|
-73
|
-94.5
|
-126
|
ROE (net income / shareholders' equity)
|
-
|
-51.6%
|
-49.9%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-33.6%
|
-27.6%
|
-43.5%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
105.1
|
244
|
288.7
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-2.260
|
8.530
|
5.410
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.02
|
-
|
2.71
|
0.19
|
-
|
-
|
-
|
0.97
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
24.99%
|
Announcement Date
|
3/24/20
|
3/25/21
|
3/17/22
|
3/9/23
|
3/12/24
|
-
|
-
|
-
|
Last Close Price
5.97
USD Average target price
12.6
USD Spread / Average Target +111.06% Consensus |
1st Jan change
|
Capi.
|
---|
| +18.15% | 124B | | +18.02% | 112B | | +5.07% | 22.94B | | -12.75% | 22.22B | | -9.86% | 17.02B | | -14.97% | 16.88B | | -39.94% | 16.87B | | +2.80% | 13.63B | | +27.39% | 11.61B |
Bio Therapeutic Drugs
|